Previous 10 | Next 10 |
ImmunityBio (NASDAQ:IBRX) is trading ~11% higher in the pre-market on Tuesday after reporting data from its late-stage bladder cancer trial (QUILT-3.032) for Anktiva (N-803), the company’s experimental cytokine infusion protein. In cohort A consisting of 83 patients with BCG-...
Results confirm prolonged sustained complete response, with 71% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) having a complete remission with a median duration of response of 24.1 months By contrast, historical complete respo...
Gainers: Alnylam Pharmaceuticals (NASDAQ:ALNY) +12%. ImmunityBio (NASDAQ:IBRX) +6%. Ortho Clinical Diagnostics Holdings (NASDAQ:OCDX) +5%. Qorvo (NASDAQ:QRVO) +5%. Vanda Pharmaceuticals (NASDAQ:VNDA) +4%. Losers: COMPASS Pathways P(NASDAQ:CMPS) +-5%. GreenSky (NASD...
ImmunityBio (NASDAQ:IBRX) announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer (NK) cells in people living with HIV by it’s IL-15 superagonist Anktiva (N-803). Anktiva stimulates latent HIV replication (the “kick”) ...
Data from the Phase 1 “HIV Cure” Study as published in Nature Medicine showed that Anktiva (N-803) stimulates latent HIV replication in CD4+ cells (the kick) and increases immune cell activation (the kill) Activated CD4, CD8, and NK immune cells are necessary for...
Last year was a big year for the stock market. Broader exchanges reached record levels with some of the most bullish optimism in recent history. Thanks to reopening efforts, new vaccines, and a strengthening economy, investors shrugged off inflation and rate-hike fears in exchange for stock...
Data show that ImmunityBio’s combination immunotherapy, Nant Cancer Vaccine, is potentially effective in pancreatic cancer where very few treatment options exist Nant Cancer Vaccine therapy more than doubles median overall survival (OS) versus historical OS in patients who ...
Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing Practices (cGMP) facility with clean rooms will expedite capabilities for large-scale m...
BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a...
NK cells engineered with a high-affinity CD16 receptor have the potential to enhance monoclonal antibody therapeutic effects against cancer cells Combination monoclonal antibody therapy and CD16 NK-92 cell therapy patent term to 2036 ImmunityBio, Inc. ( NASDAQ: IBRX ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...